Lantheus Stock Price, Forecast & Analysis (NASDAQ:LNTH)

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings data on Thursday, October, 31st. The medical equipment provider reported $0.28 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.21 by $0.07. The medical equipment provider had revenue of $85.80 million for the quarter, compared to analyst estimates of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. The company's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 EPS. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Lantheus.

Lantheus updated its fourth quarter earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $0.27-$0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.34. The company issued revenue guidance of $89-$91 million, compared to the consensus revenue estimate of $92.84 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Headlines about LNTH stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lantheus earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Lantheus.

Lantheus saw a decrease in short interest in October. As of October 31st, there was short interest totalling 1,210,000 shares, a decrease of 9.7% from the September 30th total of 1,340,000 shares. Based on an average trading volume of 411,400 shares, the days-to-cover ratio is presently 2.9 days. Approximately 3.2% of the shares of the stock are sold short. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Quidel (QDEL), Myriad Genetics (MYGN), Heska (HSKA), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Trinity Biotech (TRIB), GeneNews (GNWSF) and Arca Biopharma (ABIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Gerdau (GGB), Energy Transfer LP Unit (ET), Ares Capital (ARCC), Cypress Semiconductor (CY), Endocyte (ECYT), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD) and Anavex Life Sciences (AVXL).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (3.49%), Tamarack Advisers LP (1.91%), Rice Hall James & Associates LLC (1.09%), Peregrine Capital Management LLC (0.56%), Russell Investments Group Ltd. (0.41%) and Mackay Shields LLC (0.41%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Vaughan Nelson Investment Management L.P., Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC, Cadence Capital Management LLC, Hancock Whitney Corp and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

LNTH stock was bought by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, Tealwood Asset Management Inc., Hussman Strategic Advisors Inc., Chicago Equity Partners LLC, First Quadrant L P CA and California Public Employees Retirement System. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $20.14.

Lantheus has a market capitalization of $790.45 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]